STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more
Food and Drug Administration has shelved the fast-track drug review initiative launched during the Trump administration by former Commissioner Marty Makary, Reuters reports.
Key points
- We will trot out a bit of insight from the Morning Mayor, who would say “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing a fresh cuppa stimulation and invite you to join us.
- No new drugs have gotten a voucher since Makary’s departure, and a key component of the program — an executive council of political appointees that oversaw drug reviews and had a central role in speeding approvals — has gone dormant.
- 18 and, if it passes, her nomination would then go to the full Senate, where Republicans are racing to confirm nominees before Democrats take power in January.
Senate health committee has scheduled a pivotal vote for next week on the nomination of Heidi Overton to serve as FDA commissioner, despite lingering doubts from Republicans on the panel, STAT writes.
Additional details
- But critics pointed to possible preferential treatment for companies meeting demands of President Trump, such as offering drugs at lower prices.
- But even as he scheduled the vote, committee Chair Bill Cassidy (R-La.) remained undecided on Overton, he wrote in a post on X.
- Continue to STAT+ to read the full story….
- It would take just one Republican on the committee to sink her nomination, assuming all Democrats vote against her.
- Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.